bluuebunny/crossref_metadata_2025_split huggingface dataset:
Results of surgical treatment of colorectal cancer liver metastases in Latvia oncology center.
Authors: Sivins Armands , Lauka Lelde , Ancans Guntis , Gerkis Sergejs , Pcolkins Andrejs , Krumins Viesturs , Nemiro Ineta , Strazdina Arta , Kreice Ilona , Plate Signe , Kasperova Svetlana , Boka Viesturs , Leja Marcis 
Published: February 2017

485 Background: Colorectal cancer (CRC) is the third leading cause of cancer death. At the time of diagnosis 25% of patients present with stage IV disease and out of all CRC patients 50% develop liver metastases. About 15% of them have initially resectable disease. Surgical resection is the best treatment option as it is associated with longer survival. Latvia Oncology center (LOC) provide expertise in managment of all cancers, including metastatic CRC. Methods: Data about CRC patients with surgicaly treated liver metastases was colected and analysed from Latvia Oncology center in period 2011-2014. This data is also included in LiverMetSurvey international registry of patients operated for CRC liver metastases. 66 patients underwent hepatectomies, 10 patients had 2 or more surgeries due to a reccurent disease. Results: 77 surgeries were performed, 31 were hemihepatectomies and 46 were limited resections. Sinchronous surgery for liver metastases and primary tumor were performed in 19 cases: 11 for left colon cancer, 6 for rigt colon cancer and 2 for rectal cancer. Initially resectable liver disease was found in 70 cases. Unilateral metastases were diagnosed in 61 cases while there were 17 cases of bilateral disease. Postoperative complications developed in 18 patients, 5 of those after sinchronous surgeries for primary tumor. In 10 cases complications developed after major anatomical right sided hemihepatectomy and in 8 cases after atypical resections. Most frequent hepatic complications were infected collection in hepatic loge (n=9), non infected collection (n=3) and biliary leak (n=3); all of those were successfully treated with percutaneous dreinage. 1 patient died due to a postoperative liver insufficiency after right sided hemihepatectomy for recurrent disease. Conclusions: Overall 77 hepatectomies were performed, mostly limited non anatomical resections. In majority of patients 1 or 2 metastases were diagnosed. Initally resectable were 89% of cases. Mass of postoperative complications developed after major hepatectomies, were liver related and successfully treated with minimally invasive procedures. Complication rate (16%) in LOC is comperable to other Europian centers.
Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients.
Authors: Murakawa Masaaki , Aoyama Toru , Katayama Yusuke , Asari Masahiro , Sawazaki Sho , Yamaoku Koichiro , Kanazawa Amane , Higuchi Akio , Kobayashi Satoshi , Shiozawa Manabu , Yamamoto Naoto , Yukawa Norio , Yoshikawa Takaki , Ohkawa Shinichi , Rino Yasushi , Masuda Munetaka , Akaike Makoto , Morinaga Soichiro 
Published: February 2017

486 Background: The safety and feasibility of starting S-1 adjuvant chemotherapy for pancreatic cancer has not been evaluated in elderly patients. Methods: The patients who underwent curative D2 surgery for pancreatic cancer were selected to this retrospective study. The patients were diagnosed within stage I to III disease, and received adjuvant S-1 at our hospital. Patients were categorized into two groups; non-elderly patients (age<70 years: group A) and elderly patients (age≥70 years: group B). The toxicity and drug continuation rates in the two groups were compared. Results: Total 40 patients were evaluated in this study. There were no grade 3 and 4 toxicities. The incidences of grade 2 hematological toxicities were 0% in group A and 11% in group B. The incidences of grade 2 non-hematological toxicities were 50% in group A and 27.8% in group B. The differences in both groups were not significant. The continuation rate at 6 months was 55.7% in group A and 72.7% in group B, and there was also no significant difference in the groups. Conclusions: These results suggest that S-1 adjuvant chemotherapy for pancreatic cancer is safe and feasible, regardless of the age of the patient; especially in elderly patients.
Therapy response of Chinese herbal medicine in primary liver cancer.
Authors: Gong Yongling 
Published: February 2017

488 Background: Aiming at starting the ball rolling and contributing humble effort to promote Chinese traditional medicine, we report successful cases of Chinese herbal decoction for primary liver cancer. Methods: Conventional therapy of surgical resection and artery catheterization chemotherapy was applied in cases reported. In the meantime, we administered Chinese medicine (Gan Decoction, mixed with a variety of effective herbal components) to help them to recover from poor condition. Results: After taking the Chinese herbal decoction for months, the tumour marker (AFP, CA19-9) level dramatically decreased to the normal range. Most residual intrahepatic metastatic sites reduced according to ultrasonography/CT imaging, and the patient felt free from the complaint of abdominal discomfort. The quality of life has been greatly improved, we managed to have prolonged the PFS (Progression-Free-Survival) and TTP (Time-to-Progression) from the onset to date. Conclusions: Chinese medicine considers human body as a dynamic platform in which all organs are correlative and bind each other. Each case showed distinguished liver cancer progression and heterogeneity with individual therapy response. Our report suggested that Chinese herbs might be an additional choice with its better benefits and tolerability in the treatment of primary liver cancer.
Cross-sectional analysis of patients with non-mGC in China: An update of EVIDENCE gastric cancer registry study.
Authors: Wang Xin , Ji Jiafu , Zheng Zhichao , Zhang Helong , Zhou Weiping , Su Wuyun , Luo Qi , Guo Qunyi , Li Xiaoyi , Tang Yong , Xu Jian-Ming , Tao Feng , Li Wei , Li Xiaoqin , Qin Shukui , Yu Eric Chi-Wang , Yang Chen , Shen Lin 
Published: February 2017

49 Background: According to WHO estimation, > 400,000 new cases of gastric cancer have occurred in 2012 in China, making it the second most common malignancy in the country. However, little is known about epidemiological data of gastric cancer in China. This analysis aimed to evaluate clinicopathological and socioeconomic characteristics of Chinese patients with non-mGC. Methods: EVIDENCE was a prospective registry study. 2,600 patients with newly diagnosed gastric cancer from 85 hospitals across China were planned to be enrolled into this study. Patients who have histopathologically confirmed diagnosis of gastric cancer and corresponding HER2 IHC status diagnostic results within 6 months before enrollment are eligible. According to overall stage of disease, HER2 status, and use of trastuzumab (Herceptin®), patients are continuously assigned to 5 different cohorts until number of patients has reached the designated limit of each cohort. Results: Until 31st May 2014, 885 eligible patients were continuously enrolled before completion of recruitment of any cohort. Of these patients, 538 (60.8%) patients who were diagnosed with non-mGC were included in this analysis. In this population, 15.6% of these patients were HER2-positive (IHC3+ or IHC2+/ISH+), 73.6% were male, median age of diagnosis was 60 (range: 26-85). 75.3% (403/535) of patients were diagnosed with upper endoscopy, 65% (348/535) with biopsy, and 23.9% (128/535) with surgery. Primary tumor site of 37.2% (191/514) of patients was at the antrum (the lower third of stomach), 22.8% (117/514) was at the body (the middle third of stomach), 17.7% (91/514) was at the gastro-oesophageal junction, and 10.9% (56/514) was at the fundus (the upper third of stomach). 43.0% were former or current smokers, 30.3% had reported light to moderate alcohol consumption habit. Most of the patients (39.5%) had completed primary education or below, 53.6% reported their family annual income of RMB 35,000 (US$5,700) or below. Conclusions: Analysis of clinicolpathological and socioeconomic characteristics of Chinese patients with GC will help to improve disease management of these patients. Patient recruitment and additional analyses will be continued as planned. Clinical trial information: NCT01839500.
Endoscopic response evaluation of gastric primary lesion for chemotherapy compared to CT in advanced gastric cancer.
Authors: Chin Keisho , Yamamoto Yorimasa , Fujisaki Junko , Ogura Mariko , Shinozaki Eiji , Suenaga Mitsukuni , Mizunuma Nobuyuki 
Published: February 2017

50 Background: Significance of evaluation of gastric primary lesion with endoscopy remains unclear in chemotherapy (CTx) for advanced gastric cancer (AGC). Endoscopic evaluation is not necessary in RECIST. Methods: We compare the response of chemotherapy using RECIST by CT with or without upper GI endoscopy in AGC cases retrospectively. Among 175 cases of unresectable AGC treated by CTx in our institution between 2004 and 2008, we reviewed 141 evaluations in 74 cases which were examined by both endoscopy and CT within 2 weeks before and after CTx. Results: Patient backgrounds: Gender; M47/F27, Age; median 59(24-75), PS; 0or1=71/2=3, histological type; intestinal28/diffuse46, metastatic site; LN47/liver26/peritoneum29, CT per case; median number 4.5/ median interval 64.5days, endoscopy per case; median number 2/ median interval 91.3days. Response evaluation for gastric primary lesion between CT and endoscopy was compared in 141 examinations. Identical response 123(87.2%); both non-CR/non-PD 101/ both PD 22, not identical response 10(7.1%); endoscopy PD /CT non-CR/non-PD 10, not detected by CT; 8(5.7%). All of the cases of not identical response between CT and endoscopy were PD in endoscopy whereas non-CR/non-PD in CT. The overall response evaluation with or without endoscopy was concord in 133 evaluations (94.3%). Conclusions: It is almost appropriate that response evaluation of chemotherapy in AGC is mainly performed by CT without endoscopy to primary gastric lesion.
HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) to predict toxicity in stage III colon cancer (CC) patients (pts) (NCCTG Alliance N0147).
Authors: Lee Adam M , Shi Qian , Alberts Steven R. , Sargent Daniel J. , Sinicrope Frank A. , Berenberg Jeffrey L. , Goldberg Richard M. , Diasio Robert B. 
Published: February 2017

508 Background: Severe adverse events (AEs) to 5-fluorouracil (5-FU) constitute a major dilemma in CC treatment. We recently demonstrated that specific deleterious DPYD variants in the coding region were highly predictive of grade >3 (G3+) AEs in stage III CC pts receiving adjuvant 5-FU based combination chemotherapy [Lee et al. JNCI. In press]. Other studies have suggested potential associations between AEs and non-coding DPYD variants: a novel haplotype (HapB3) containing three intronic variants (c.483+18 G>A, c.680+139 G>A, and c.959-51 T>C), one synonymous variant (c.1236 G>A, E412E), and a deep intronic variant (c.1129-5923 C>G) that affects pre-mRNA splicing. However, these studies included a diversity of cancer types, stages and treatments. The findings require further evaluation in a refined population. Methods: A total of 2,134 Caucasian stage III CC pts without DPYD*2A, D949V, and I560S variants from NCCTG N0147 trial who received adjuvant FOLFOX or FOLFIRI +/- cetuximab were genotyped by multiplexed single-base extension assays on the Sequenom MassARRAY. G3+ AEs were recorded (CTCAE v3) and classified as common to 5-FU treatment (5FU-AEs). Logistic regressions were used to assess the univariate and multivariate associations. Results: Analyzed pts displayed the following characteristics: 54.3% male, median age 59 [19-85], proficient MMR 87.5%, PS-0 76.5%, + irinotecan 8.5%, and + cetuximab 46.5%. Pts carrying c.1129-5923 C>G were significantly associated with higher risk of G3+ 5FU-AEs (Odds Ratio [OR]=1.539, 95% confidence interval [CI]=1.001 – 2.367, p=0.049). Only marginal association was observed for one of the HapB3 variants, c.1236 G>A (p=0.058). A linearly increasing risk of G3+ 5FU-AEs was identified for HapB3, comparing pts with no, one or >1 variant present (unadjusted OR=1.539, 95% CI=1.001 – 2.367, p=0.041; adjusted OR=1.198, 95% CI=0.998-1.437, p=0.052). Conclusions: In the largest study to date, c.1129-5923 C>G and HapB3 were predictive of 5FU-AE risk in stage III CC patients without DPYD*2A, D949V, and I560S variants receiving 5-FU-based combination chemotherapy.
Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.
Authors: Stintzing Sebastian , Modest Dominik Paul , Fischer von Weikersthal Ludwig , Decker Thomas , Kiani Alexander , Vehling-Kaiser Ursula , Al-Batran Salah-Eddin , Heintges Tobias , Lerchenmuller Christian A. , Kahl Christoph , Seipelt Gernot , Kullmann Frank , Stauch Martina , Scheithauer Werner , Held Swantje , Giessen Clemens Albrecht , Moehler Markus Hermann , Jung Andreas , Kirchner Thomas , Heinemann Volker 
Published: February 2017

515 Background: The FIRE-3 study (AIO KRK-0306) was designed to compare the efficacy of FOLFIRI + cetuximab (cet) to FOLFIRI + bevacizumab (bev) as first-line treatment in KRAS WT mCRC patients. FOLFIRI plus cet resulted in comparable overall response rates (ORR) and progression free survival (PFS) when compared to FOLFIRI + bev. Overall survival (OS) was significantly longer in the FOLFIRI + cet arm. Methods: In an exploratory subgroup analysis, patients pretreated with adjuvant chemotherapy were analyzed by Fisher's exact and log rank-test according to tumor response (ORR) and survival data. Patients of the ITT (n=592) and the final RAS wild-type population (n=400) were investigated. Results: See table. Conclusions: Results in patients treated with any adjuvant chemotherapy mirrored those in the whole study population. In adjuvant pretreated RASwt patients a significantly higher ORR was reached in the cet arm when compared to the bev arm (p=0.01). The role of adjuvant treatment on efficacy of first-line therapy remains to be further evaluated. Clinical trial information: NCT00433927. [Table: see text] [Table: see text]
The diagnostic value of the immunochromatographic fecal tumor M2 pyruvate kinase test as a screening tool for colorectal malignant lesions.
Authors: Kim Jin Il , Kim Jae J. 
Published: February 2017

517 Background: The M2 pyruvate kinase (M2-PK) is known as a specific enzyme produced in undifferentiated and proliferating tissues. However, the fecal tumor M2-PK ELISA test is expensive and time consuming, and also needs an available laboratory. For this reason, in the same way as immunochromatographic fecal occult blood test (iFOBT), an immunochromatographic fecal tumor M2-PK test (iM2-PK), has recently been developed. This is the study for the diagnostic value of the iM2-PK as a screening test for colorectal malignant and premalignant lesions. Methods: A total of 323 individuals participated. iFOBT and iM2-PK were performed with the stool samples. The participants consisted of 60 healthy volunteers, 124 patients with colonic adenoma, and 139 patients with colorectal cancer (CRC). The fecal tumor M2-PK ELISA tests were performed with the rest of stool samples from 68 participants, consisting of 40 patients with CRC, 26 patients with colonic adenoma, and 2 healthy volunteers. Results: For diagnosing CRC, the sensitivity, specificity, and area under the curve (AUC) were 92.8%, 83.3%, and 0.88 in iM2-PK, and 47.5%, 83.3%, and 0.65 in iFOBT. For diagnosing adenoma, the sensitivity, specificity, and AUC were 69.4%, 83.3%, and 0.76 in iM2-PK, and 12.1%, 83.3%, and 0.52% in iFOBT. The diagnostic accuracy of iM2-PK by using AUC was significantly higher than that of iFOBT for diagnosing CRC and adenoma (p< 0.05). In ELISA study, the sensitivity for CRC was 97.5% in iM2-PK, 47.5% in iFOBT, and 80.0% in fecal tumor M2-PK ELISA test. The sensitivity for adenoma was 69.2% in iM2-PK, 19.2% in iFOBT, and 61.5% in fecal tumor M2-PK ELISA test. The sensitivity of iM2-PK for diagnosing CRC was superior to that of iFOBT and M2-PK ELISA test (p< 0.05). Conclusions: iM2-PK is a rapid and cost-effective test for diagnosing CRC and colonic adenoma, and can easily performed in outpatient clinics. iM2-PK is a useful test in screening for CRC and colonic adenoma.
Prevalence of RAS mutations among patients with metastatic colorectal cancer by country and region in randomized clinical trials: A pooled analysis.
Authors: Peeters Marc , Kafatos George , Taylor Aliki , Gastanaga Victor M. , Yu Hua , Oliner Kelly Smith , Maglinte Gregory A. , Terwey Jan-Henrik , Krieken Han H. J. M. 
Published: February 2017

520 Background: Global mCRC treatment guidelines for EGFR inhibitors require prior confirmation of wild-type RAS status (KRAS exons 2, 3, 4 and NRAS 2, 3, 4). The aim of this study was to estimate the prevalence of RAS mutations among mCRC patients by country, demographic characteristics, and clinical risk factors. A secondary aim was to estimate BRAF and KRASexon 2 mutation prevalence. Methods: Data from 5 published Amgen-sponsored randomized clinical trials (RCTs) were merged in a retrospective pooled analysis. There were 3 phase III, 1 phase II, and 1 phase Ib/II studies. For 4 out of 5 RCTs, RAStesting was conducted in a U.S. laboratory (Transgenomic Inc.) using Sanger sequencing on DNA extracted from tumor samples. For the remaining trial, a combination of next-generation sequencing and Sanger sequencing was used. Results: A total of 3,196 patients from 36 countries were included. The overall unadjusted prevalence of RAS mutations among mCRC subjects was 55.9% (95% CI, 53.9%, 57.9%); KRAS exon 2 mutation prevalence was 42.6% (40.7%, 44.5%). The prevalence by exon is given in the table below. BRAFmutation prevalence was 8.1% (6.7%, 9.6%). There were no statistically significant differences in RAS mutation prevalence by gender, age, or clinical factors such as performance status, tumour site, biopsy origin, or metastasis characteristics. Statistically significant differences in RAS mutation prevalence estimates were observed by country and by region with rates for Central West Europe being significantly lower than Eastern Europe (49.4% [44.4%, 54.3%] and 61.5%; [55.3%; 67.4%] respectively). Statistically significant RASmutation prevalence differences were observed between studies which could be due to varying patient characteristics. Conclusions: By merging data from RCTs, the analysis provides robust estimates of RASmutation prevalence. Studies using observational data are needed to confirm these findings. [Table: see text]
Temporal trends in colorectal cancer stage and presentation since the introduction of a national bowel screening program.
Authors: Mansouri David , Crearie Christine , Mcmillan Donald C. , Crighton Emilia M. , Horgan Paul G. 
Published: February 2017

522 Background: Screening for colorectal cancer using the fecal occult blood test (FOBt) reduces cancer specific mortality through the detection of early stage disease. However, population screening programs are limited by both uptake and the sensitivity of the test. The present study aimed to examine the effect of a national screening program on TNM stage and presentation in our geographical region. Methods: A biennial FOBt screening program, inviting all males and females aged 50 to 74 years, was introduced in 2007 in a stepwise manner across the region with full coverage achieved by 2011. Regional cancer audit databases and national population statistics were examined to compare Early screening introduction (2007/8), Late screening introduction (2009/10) and Post screening (2011/12) time periods. Results: In a population of 2.4 million, over a 6 year period, 9,723 patients were diagnosed with colorectal cancer (3098 Early; 3282 Late; 3343 Post). There was a small overall increase in incidence during the study period (0.064%/year Early vs 0.068%/year Post, p=0.017). This increase remained when adjusting for sex in both males and females. There was no difference in the age, sex or socioeconomic deprivation status of patients across the three time periods. The proportion of screen-detected cancers increased over time (3% Early vs 18% Post, p<0.001) with a concomitant fall in elective symptomatic presentations (62% Early vs 47% Post, p<0.001). No difference in the proportion of emergency presentations was seen (13% Early vs 13% Post, p=0.282). There was no difference in tumor site (p=0.692) or overall TNM stage at diagnosis (p=0.548) over time. However, when those presenting with non-metastatic disease were examined separately, there was clear trend towards earlier stage disease (18% Stage 1 Early vs 28% Stage 1 Late, p<0.001). Conclusions: Despite only accounting directly for a limited proportion of all tumors detected, the introduction of a national screening program has been accompanied by a stage shift in colorectal cancer disease towards earlier presentation. Further work is required to target those more likely to present as an emergency as they appear resistant to the current program.
Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global Aflibercept Safety and Quality-of-Life Program in pts pretreated with bevacizumab (B).
Authors: Sobrero Alberto F. , Bordonaro Roberto , Bencardino Katia , Pietrantonio Filippo , Bauer Stefan , Taïeb Julien , Garreau-Laporte Pascale , Zilocchi Chiara , Dochy Emmanuelle , Lledo Gérard 
Published: February 2017

528 Background: In the VELOUR study, adding ziv-aflibercept (Z) (known as aflibercept outside the United States) to FOLFIRI resulted in improved OS, PFS, and RR in metastatic colorectal cancer (mCRC) patients (pts) who had received prior oxaliplatin. Prior treatment with bevacizumab (B) did not appear to impact safety profile of Z. The global ASQoP/AFEQT studies are 2 clinical studies (ASQoP [NCT01571284]; AFEQT [NCT01670721]) designed to capture QoL and safety data from a population similar to VELOUR but treated in a real-life setting. We report safety data from the 4th interim analysis in B-pretreated pts. Methods: ASQoP/AFEQT are single-arm, open-label trials of Z in mCRC pts previously treated with an oxaliplatin-containing regimen. Eligible pts receive Z (4 mg/kg) q2w on day 1 of each cycle followed by FOLFIRI until disease progression, unacceptable toxicity, death, or investigator/pt decision. Initial starting doses of FOLFIRI and subsequent modifications are at treating physician’s discretion. % of pts with grade (G) 3 or 4 AEs in the combined B-pretreated safety population of ASQoP/AFEQT is compared with B-pretreated pts in the Z + FOLFIRI arm of VELOUR. Results: At data cutoff, overall safety population comprised 688 pts with ≥1 completed treatment cycle; 343 (49.9%) were B-pretreated. Currently, median number of cycles administered to ASQoP/AFEQT pts is 6; in VELOUR, pts in Z + FOLFIRI arm had a median of 9. Table shows summary of TEAEs in B-pretreated pts. Conclusions: Thisinterim safety analysis of ASQoP/AFEQT in B-pretreated pts identified no new safety signals for Z and a trend toward decreased G3/4 events. The analysis provides additional safety data suggesting an acceptable toxicity profile in a real-life setting. Clinical trial information: NCT01571284. [Table: see text]